A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism
نویسندگان
چکیده
منابع مشابه
A New Experience in Treatment of Congenital Hyperinsulinism with Long Acting Octreotide: A Case Report
Histologically, congenital hyperinsulinism may be broadly classified into focal and diffuse forms. Although they present with similar clinical manifestations, they differ in the management required. Focal forms of CHI, unlike the diffuse forms are amenable to surgery without any long term sequlae [4]. Owing to the fact that, near-total pancreactectomy often leads to postoperative hypoglycemias ...
متن کاملSuccessful treatment of congenital hyperinsulinism with long-acting release octreotide.
CONTEXT Congenital hyperinsulinism (HI) is a common cause of hypoglycemia in infancy. The medical treatment of diazoxide-unresponsive HI is based on a somatostatin analogue. OBJECTIVE This study aims at replacing three daily s.c. octreotide (Sandostatin, Novartis) injections by a single and monthly i.m. injection of long-acting release (LAR) octreotide (Sandostatin LP, Novartis) in HI patient...
متن کاملPrescription patterns of long-acting somatostatin analogues
BACKGROUND Acromegaly and endocrine tumors are uncommon morbidities that are currently treated with different drugs. OBJECTIVE To determine the prescription patterns of somatostatin analogues in patients affiliated with the Health System of Colombia. METHODS Retrospective cohort study of patients of any age and sex treated with octreotide or lanreotide between January 2011 and August 2015. ...
متن کاملLong-term follow-up of 114 patients with congenital hyperinsulinism.
BACKGROUND The term congenital hyperinsulinism (CHI) comprises a group of different genetic disorders with the common finding of recurrent episodes of hyperinsulinemic hypoglycemia. OBJECTIVE To evaluate the clinical presentation, diagnostic criteria, treatment and long-term follow-up in a large cohort of CHI patients. PATIENTS The data from 114 patients from different hospitals were obtain...
متن کاملSomatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
BACKGROUND Growth hormone-secreting pituitary adenomas (somatotroph adenoma) predominantly express somatostatin receptors (SSTRs) subtypes 2 and 5. Higher SSTR2 expression on somatotroph adenomas results in a better response to somatostatin analogues (SSAs), which preferentially bind, but also downregulate, SSTR2. The effect of the combined treatment with SSAs and the GH receptor antagonist peg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hormone Research in Paediatrics
سال: 2017
ISSN: 1663-2818,1663-2826
DOI: 10.1159/000485184